After successfully implanting the neuromodulation device BAROSTIM NEO, Hackensack University Medical Center became the first hospital in the nation to use the product commercially.

The Woman-to-Woman program was first established in New York in 2004 and has since been implemented in more than 40 hospitals and community-based organizations throughout the county.

According to a lawyer for the plaintiffs and the company, the $750 million in punitive damages will be reduced significantly due to state laws.

"The state of the pharmaceutical industry in the state is growing, getting stronger and doing really important things," President and CEO Debbie Hart told NJBIZ.

The system's 'Healthy schools, Healthy Families' mantra is informing its work to establish monthly food pantries at schools and expand offering at its health care centers with "farmacy" initiatives.

On Feb. 5, the generic pharmaceutical company announced Jason Grenfell-Gardner would leave the company, and named his successor.

The legislation, which was signed into law in January, requires pharmacists to provide written and oral information on medication disposal, and safe methods for doing so, for all controlled substances.

Christ Hospital, a CarePoint Health facility, entered into an agreement in October 2019 to be acquired by RWJBarnabas Health.

"As we work to improve public health with health providers and plans, mayors and health officers, as well as state officials, these results provide invaluable insight into who are the most trusted messengers and where the public goes to find out this information," said Linda Schwimmer, president and chief executive officer of the Quality Institute, which partnered with Eagleton Center for Public Interest Polling at Rutgers University-New Brunswick on the Health Matters poll.

The company, which is expected to based in New Jersey, will see the shift of nearly 90 products representing $6.5 billion in total revenue.

The facility will provide for the development of the state's only oncology inpatient hospital, expand service offerings to patients and provide access to multidisciplinary clinics.

Somerset-based Catalent Inc. agreed Feb. 3 to acquire MaSTherCell Global Inc. a company backed by Great Point Partners, SFPI-FPIM, and Orgenesis Inc. for $315 million in cash. “MaSTherCell extends our leadership position in the biotech industry, complements our leading gene therapy offering, and allows us to deliver comprehensive development, manufacturing, analytical, fill-finish, and clinical supply solutions ...